Drug Discovery in Canine Pyometra Disease Identified by Text Mining and Microarray Data Analysis

Table 3

The specified information of drugs and their target genes.

Number	Gene	Drug	Interaction	Drug class
1	BTK	Ibrutinib	Inhibitor	Antineoplastic agents
2	BTK	Dasatinib	Other	Antineoplastic agents
3	CSF2RA	Sargramostim	Agonist	Immunomodulatory agents
4	CSF2RB	Sargramostim	Agonist	Immunomodulatory agents
5	ITGAL	Busulfan	Other	Not available
6	ITGAL	Etoposide	Other	Not available
7	ITGAL	Fluorouracil	Other	Not available
8	ITGAL	Cyclosporine	Other	Immunosuppressive agents
9	ITGAL	Sirolimus	Other	Immunosuppressive agents
10	ITGAL	Cyclophosphamide	Other	Not available
11	NCF4	Idarubicin	Other	Antineoplastic agents
12	NCF4	Doxorubicin	Other	Antineoplastic agents
13	PLCG2	Ibrutinib	Other	Antineoplastic agent
14	PTPRC	Adalimumab	Other	Anti-inflammatory agent
15	PTPRC	Etanercept	Other	Immunomodulatory agents, anti-inflammatory agent
16	PTPRC	Infliximab	Other	Immunosuppressive agents, anti-inflammatory agent
17	PTPRC	Prednisone	Other	Anti-inflammatory agent
18	PTPRC	Fluorouracil	Other	Not available
19	PTPRC	Hydrocortisone	Other	Not available
20	TOP2A	Etoposide	Inhibitor	Antineoplastic agents
21	TOP2A	Dexrazoxane	Inhibitor	Not available
22	TOP2A	Teniposide	Inhibitor	Antineoplastic agents
23	TOP2A	Amsacrine	Inhibitor	Not available
24	TOP2A	Idarubicin	Inhibitor	Antineoplastic agents
25	TOP2A	Doxorubicin	Inhibitor	Antineoplastic agents
26	TOP2A	Mitoxantrone	Inhibitor	Antineoplastic agents
27	TOP2A	Epirubicin	Inhibitor	Antineoplastic agents
28	TOP2A	Daunorubicin	Inhibitor	Antineoplastic agents
29	TOP2A	Vincristine	Other	Antineoplastic agents

Note: the drug indications have been approved by FDA. BTK: Bruton’s tyrosine kinase; CSF2RA: colony-stimulating factor 2 receptor alpha; CSF2RB: colony-stimulating factor 2 receptor beta; ITGAL: integrin subunit alpha L; NCF4: neutrophil cytosolic factor 4; PLCG2: phospholipase C-gamma 2; PTPRC: protein phosphatase; TOP2A: topoisomerase II alpha.